利奈唑胺与替考拉宁治疗老年MRSA肺炎的疗效观察

目的比较恶唑烷酮类抗生素利奈唑胺与糖肽类抗生素替考拉宁治疗老年耐甲氧西林金黄色葡萄球菌（MRSA）肺炎的临床疗效及安全性。方法对18例接受替考拉宁治疗和11例接受利奈唑胺治疗的老年MRSA肺炎患者的临床治愈率、细菌清除率及不良反应发生率等进行比较。结果利奈唑胺组治愈率72．7％，细菌清除率81．8％，不良反应发生率10％；替考拉宁组治愈率27．8％，细菌清除率38．9％，不良反应发生率11％。结论利奈唑胺组治疗老年MRSA肺炎临床疗效优于替考拉宁组，可安全地应用于老年患者。

Curative-effect observation of Linezolid and Teicoplanin for gerontal-patients with MRSA-related pneumonia

Objective To compare the clinical therapeutics and medication safety of Linezolid （oxazolidinone antibacterial） and Teicoplanin （glycopeptides a ntibacterial） in gerontal-patients with MRSA （Methieillin-resistant Staphylococcus Aureus）-Related Pneumonia treatment. Methods Compared the cure rate, bacterium clearance rate and adverse-effect incidence rate in Teicoplanin group （include 18 patients） and Linezolid group （include 11 patients）. Results Teicoplanin group： cure rate was 27.8%, bacterium clearance rate was 38.9%, adverse-effect incidence rate was 11%; linezolid group： cure rate was 72.7%, bacterium clearance rate was 81.8%, adverse-effect incidence rate was 10%. Conclusion Linezolid has advantages compared with Teicoplanin, in clinical using which including therapeutics-choice and safety-concern for gerontal-patients with MRSA-related pneumonia.